KRAS and neoplasm: Three patients had at least one activating KRAS alteration and/or KRAS amplification detected in all samples, with the ERBB2 amplification occurring in the last sample, notably corresponding to an increase in tumor shed, as measured via the maximum variant allele frequency (maxVAF) in the sample.